STOCK TITAN

Becton Dickinson insider files Form 144 to sell 917 shares via Merrill Lynch

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Becton, Dickinson and Co. (BDX) Form 144 shows a proposed sale of 917 common shares through Merrill Lynch on 09/10/2025, with an aggregate market value of $171,862.50. The filer acquired these shares as a stock bonus on 01/23/2025 from Claire Marie Fraser and paid by stock bonus on the same date. The filing also discloses a recent sale of 863 shares on 08/08/2025 for gross proceeds of $165,879.90. Outstanding shares are listed as 286,627,469, making these transactions a very small fraction of total shares outstanding.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider plans a routine sale of newly received stock bonus totaling 917 shares; transaction size is immaterial to BDX capitalization.

The Form 144 documents a proposed sale and a recent sale by or for the account of a person who received a stock bonus. The proposed sale value of $171,862.50 versus total outstanding shares of 286,627,469 implies a de minimis ownership impact. There is no disclosure here of material nonpublic information or unusual trading arrangements; acquisition and payment are recorded as stock bonus. From a market-impact perspective, this filing appears routine and not material to investors.

TL;DR: Filing meets Rule 144 disclosure of proposed insider sale; no governance or compliance red flags evident from the form.

The form includes the required representations about lack of material nonpublic information and documents the broker, dates, quantities, and consideration (stock bonus). The inclusion of a prior sale in the three-month window (863 shares) provides useful transaction history. Absent additional context or related-party complexity, this appears to be a standard Rule 144 notice consistent with regulatory expectations.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does BDX Form 144 filed for 09/10/2025 disclose?

The Form 144 discloses a proposed sale of 917 common shares through Merrill Lynch on 09/10/2025 with aggregate market value $171,862.50.

How were the 917 BDX shares acquired?

The filer acquired the 917 shares on 01/23/2025 as a stock bonus from Claire Marie Fraser, with payment recorded as stock bonus.

Did the filer sell any BDX shares recently?

Yes, the filing reports a sale on 08/08/2025 of 863 shares for gross proceeds of $165,879.90.

How large are these transactions relative to BDX shares outstanding?

Outstanding shares are listed as 286,627,469, so the proposed sale of 917 shares represents a negligible fraction of total shares.

Who is the broker handling the proposed sale?

The broker listed is Merrill Lynch at the address shown in the filing.
Becton Dickinson & Co

NYSE:BDX

BDX Rankings

BDX Latest News

BDX Latest SEC Filings

BDX Stock Data

57.34B
283.68M
0.57%
92.26%
1.59%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
FRANKLIN LAKES